Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5051
Revised: July 7, 2013
Accepted: July 19, 2013
Published online: August 21, 2013
Core tip: Modern targeted therapy with anti-angiogenic agents is based on inhibition of angiogenesis, as the formation of new vessels is crucial for the growth and metastasis of malignant cells. Recent studies on the biological agent, bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor activity, have shown improved outcome in advanced colorectal cancer. The combination of irinotecan, capecitabine and bevacizumab is currently the most frequently used regime in the treatment of metastatic colorectal cancer with improved response rates. However, the rare side-effects of bevacizumab should always be considered.